APSR2026-1036

 
Late-Breaking
Submitted
Oral Presentation
AO24-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1211243-46903-Oral presentation.APSR2026-1036_441012.pptx
Format: PPTX Only
 
Format: PDF Only
16. Interstitial Lung Disease
9

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Shoichiro Saito * Kobe City Medical Center General Hospital Respiratory Medicine Kobe Japan
Takumi Fukaya - Tokyo Metropolitan Tama Medical Center Respiratory Medicine and Oncology Fuchu Japan
Masaaki Ibe - Kobe City Medical Center General Hospital Respiratory Medicine Kobe Japan
Ryo Yamamoto - Tokyo Metropolitan Tama Medical Center Respiratory Medicine and Oncology Fuchu Japan
Rina Takahashi - Tokyo Metropolitan Tama Medical Center Respiratory Medicine and Oncology Fuchu Japan
Masato Nakamura - Tokyo Metropolitan Tama Medical Center Respiratory Medicine and Oncology Fuchu Japan
Keisuke Tomii - Kobe City Medical Center General Hospital Respiratory Medicine Kobe Japan
Miyako Kitazono - Tokyo Metropolitan Tama Medical Center Respiratory Medicine and Oncology Fuchu Japan
Ryo Tachikawa - Kobe City Medical Center General Hospital Respiratory Medicine Kobe Japan
 
 
 
 
 
 
Presenting Author Details
Shoichiro
Saito
nmu12saru@icloud.com
+818014920158
Under 30
Japan
Original Research
Age above 70 years and reduced diffusing capacity predict poorer survival in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: a two-center retrospective cohort study
Maximum 25 words
Abstract Content
The GAP (Gender–Age–Physiology) model is commonly used for mortality risk stratification in idiopathic pulmonary fibrosis (IPF), but it was developed before antifibrotic therapy became widely available and may not fully reflect today's increasingly elderly IPF population. We sought to identify prognostic factors in antifibrotic-treated IPF, with particular attention to the impact of advanced age (>70 years).
In this two-center retrospective cohort, patients treated with antifibrotic agents were identified at Tokyo Metropolitan Tama Medical Center (Jan 2008–Dec 2023) and Kobe City Medical Center General Hospital (Jul 2011–Dec 2023). Of 227 patients with IPF, 128 with pulmonary function data available within 6 months of antifibrotic treatment initiation were analyzed. Among the 128 patients included, 84 (66%) were aged >70 years. The primary endpoint was 5-year overall survival from antifibrotic treatment initiation. A multivariable Cox model included age (>70 vs ≤70 years), sex, %FVC (continuous), and %DLCO (continuous). Survival was compared by age using Kaplan–Meier and log-rank methods.
Patients were mostly male (85%); mean age 72.4 years, mean %FVC 80.2%, mean %DLCO 63.6%. During 5 years, 75 (59%) died. Age >70 years (adjusted HR 1.76, 95%CI 1.06–2.90; p=0.028) and lower %DLCO (HR 0.82 per 10%, 95%CI 0.71–0.94; p=0.004) were independently associated with worse survival, whereas sex and %FVC were not. Five-year survival was 22.7% (>70 years) versus 38.1% (≤70 years). The proportional-hazards assumption held for all covariates.
In a contemporary cohort of antifibrotic-treated patients with IPF, age >70 years and reduced diffusing capacity independently predicted poorer survival. These findings suggest that age-related prognostic stratification remains relevant in the antifibrotic era.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Idiopathic Pulmonary Fibrosis, Antifibrotic Agents, Interstitial Lung Disease
maximum 3 keywords and no abbreviations, separated by commas
 
281